Aquestive Therapeutics
AQST
4.62
0.00
-0.02%
Aquestive Therapeutics
US · AQST
#3650 by market cap
Listed 2018
4.62
0.00
-0.02%
Live - 5344 symbols - heartbeat 482s ago
· 2026-10-08 10:11
Pre-market
4.50
-2.60%
After-hours
4.62
0.00%
- Market cap
- 579.74M
- P/E (TTM)i
- -7.00
- P/Bi
- -10.24
- EPSi
- -0.78
- Div yieldi
- 0.00%
- 52W posi
- 37%
Reader sentiment
Are you bullish or bearish on AQST?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -2.53, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -22.61% YoY
Margins
- Gross margin
- 58.35%
- Operating margin
- -159.50%
- Net margin
- -188.09%
Key ratios & quality
- Enterprise valuei
- 496.71M
- Altman Z-Scorei
- -2.53
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 67.43M | 52.61M | 45.85M | 50.83M | 47.68M | 50.58M | 57.56M | 44.55M |
| Gross profit | 46.44M | 32.25M | 32.89M | 35.84M | 28.29M | 29.75M | 39.69M | 25.99M |
| Selling & admin expenses | 72.27M | 64.34M | 55.89M | 53.48M | 52.88M | 31.75M | 50.18M | 79.85M |
| Research & development | 23.11M | 20.57M | 19.89M | 17.05M | 17.48M | 13.10M | 20.28M | 17.19M |
| Operating profit | -48.94M | -52.67M | -42.89M | -34.68M | -42.07M | -15.10M | -30.77M | -71.05M |
| Pretax profit | -61.38M | -66.25M | -55.78M | -70.54M | -54.41M | -7.63M | -44.15M | -83.78M |
| Tax | 0 | 0 | 0 | 0 | 0 | 245.00K | -14.00K | 0 |
| Net profit | -61.38M | -66.25M | -55.78M | -70.54M | -54.41M | -7.87M | -44.14M | -83.78M |
| Basic EPS | -3 | -3 | -2 | -2 | -1 | 0 | -1 | -1 |
| Diluted EPS | -2.96 | -2.61 | -1.66 | -1.85 | -1.12 | -0.13 | -0.51 | -0.78 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 8.72M | 10.00M | 12.81M | 13.02M | 14.45M | 13.82M |
| Gross profit | 5.07M | 5.44M | 8.30M | 7.18M | 10.98M | 9.80M |
| Selling & admin expenses | 19.07M | 12.71M | 15.25M | 32.82M | 10.98M | 14.06M |
| Research & development | 5.36M | 4.11M | 4.53M | 3.20M | 4.20M | 3.96M |
| Operating profit | -19.37M | -11.37M | -11.48M | -28.84M | -4.20M | -8.22M |
| Pretax profit | -22.93M | -13.55M | -15.45M | -31.86M | -8.06M | -22.86M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -22.93M | -13.55M | -15.45M | -31.86M | -8.06M | -22.86M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.24 | -0.14 | -0.14 | -0.26 | -0.07 | -0.18 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 74.20M | 68.31M | 44.63M | 47.26M | 39.89M | 40.97M | 88.22M | 149.27M |
| Cash & ST investments | 60.60M | 49.33M | 31.81M | 28.02M | 27.27M | 23.87M | 71.55M | 121.17M |
| Inventory | 5.44M | 2.86M | 2.46M | 4.04M | 5.78M | 6.77M | 6.04M | 6.17M |
| Total assets | 86.85M | 78.48M | 62.88M | 61.99M | 57.07M | 57.42M | 101.42M | 160.43M |
| Total current liabilities | 32.95M | 18.56M | 21.10M | 21.96M | 39.53M | 18.31M | 18.87M | 47.61M |
| Short-term debt | 4.60M | -- | 3.30M | 2.92M | 18.96M | 412.00K | 536.00K | 10.63M |
| Long-term debt | 42.60M | 60.34M | 34.33M | 51.55M | 33.45M | 27.51M | 32.50M | 27.52M |
| Total liabilities | 76,771,000.00 | 84,601,000.00 | 111,381,000.00 | 144,127,000.00 | 175,624,000.00 | 163,905,000.00 | 161,580,000.00 | 194,087,000.00 |
| Total equity | 10.08M | -6.12M | -48.50M | -82.13M | -118.55M | -106.49M | -60.16M | -33.66M |
| Retained earnings | -61.38M | -130.47M | -186.26M | -256.80M | -311.21M | -319.08M | -363.21M | -447.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 89.17M | 81.72M | 151.67M | 149.27M | 130.18M | 118.49M |
| Cash & ST investments | 68.66M | 60.54M | 129.06M | 121.17M | 110.73M | 98.49M |
| Inventory | 7.20M | 8.13M | 7.88M | 6.17M | 8.07M | 7.37M |
| Total assets | 102.23M | 93.70M | 163.56M | 160.43M | 141.13M | 132.10M |
| Total current liabilities | 18.30M | 23.16M | 25.57M | 47.61M | 31.75M | 16.48M |
| Short-term debt | 567.00K | 3.75M | 6.93M | 10.63M | 14.32M | 852.00K |
| Long-term debt | 33.75M | 31.84M | 29.94M | 27.52M | 25.10M | 50.65M |
| Total liabilities | 163,164,000.00 | 166,288,000.00 | 167,668,000.00 | 194,087,000.00 | 175,179,000.00 | 188,690,000.00 |
| Total equity | -60.93M | -72.59M | -4.11M | -33.66M | -34.05M | -56.59M |
| Retained earnings | -386.14M | -399.69M | -415.14M | -447.00M | -455.06M | -477.92M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -12.99M | -60.21M | -45.46M | -32.98M | -9.82M | -6.38M | -35.76M | -52.43M |
| Depreciation & amortization | 3.24M | 2.91M | 3.44M | 2.96M | 2.39M | 1.35M | 718.00K | 548.00K |
| Free cash flow | -14.82M | -60.87M | -45.98M | -33.89M | -12.34M | -7.38M | -35.92M | -52.99M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 68.83M | 39.32M | 6.22M | 29.78M | 13.59M | 8.91M | 83.76M | 100.65M |
| Ending cash balance | 60.60M | 49.33M | 31.81M | 28.02M | 27.27M | 23.87M | 71.55M | 121.17M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -23.40M | -7.91M | -12.65M | -8.47M | -14.81M | -9.44M |
| Depreciation & amortization | 139.00K | 140.00K | 139.00K | 130.00K | 113.00K | 136.00K |
| Free cash flow | -23.54M | -8.02M | -12.88M | -8.55M | -14.86M | -9.65M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 21.36M | -124.00K | 79.72M | -301.00K | 4.76M | -79.00K |
| Ending cash balance | 68.66M | 60.54M | 129.06M | 121.17M | 110.73M | 98.49M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -3,347.45 | -- | -- | -- | -- | -- | -- |
| ROA %i | -94.45 | -80.14 | -78.92 | -112.97 | -91.40 | -13.75 | -55.57 | -63.99 |
| ROIC %i | -- | -107.70 | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -79.59 | -108.21 | -93.26 | -94.58 | -88.02 | -0.32 | -47.49 | -149.70 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.25 | 3.68 | 2.11 | 2.15 | 1.01 | 2.24 | 4.68 | 3.14 |
| Quick ratioi | 2.04 | 3.37 | 1.84 | 1.83 | 0.81 | 1.77 | 4.18 | 2.92 |
| Debt / assetsi | 54.35 | 76.88 | 64.37 | 91.01 | 100.73 | 58.03 | 37.47 | 26.48 |
| LT debt / equityi | 422.65 | -- | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -6.96 | -6.11 | -3.28 | -2.14 | -3.37 | -0.02 | -1.63 | -3.90 |
| Revenue CAGR (3Y) %i | -- | 0.53 | -11.84 | -8.99 | -3.23 | 3.33 | 4.23 | -2.24 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -46.81 | -61.56 | -50.44 | -63.99 | -56.63 | -69.29 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -68.89 | -108.95 | -119.69 | -149.70 | -103.74 | -114.45 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.87 | 3.53 | 5.93 | 3.14 | 4.10 | 7.19 |
| Quick ratioi | 4.32 | 3.13 | 5.51 | 2.92 | 3.70 | 6.54 |
| Debt / assetsi | 38.28 | 42.97 | 25.30 | 26.48 | 30.88 | 44.69 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -2.21 | -2.83 | -3.05 | -3.90 | -3.11 | -3.79 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development and advancement of a product pipeline for the treatment of severe allergic reactions100.00%
Quote time 2026-10-08 10:11:28 · For reference only, not investment advice and not tailored to your situation.